SEC Form 4 · accession 0001562180-18-004249

REGENXBIO Inc. · RGNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Technical Operations

Period of report

Oct 16, 2018

Accepted (ET)

Oct 18, 2018 · 4:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001590877

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 16, 2018	M	46,517	$22.00	A	86,017	D
Common Stock	Oct 16, 2018	S	46,517	$60.85	D	39,500	D
Common Stock	Oct 16, 2018	M	13,125	$19.50	A	52,625	D
Common Stock	Oct 16, 2018	S	13,125	$60.85	D	39,500	D
Common Stock	Oct 16, 2018	M	2,667	$13.09	A	42,167	D
Common Stock	Oct 16, 2018	S	2,667	$60.85	D	39,500	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$22.00	Oct 16, 2018	M	46,517	D	—	Aug 30, 2025	Common Stock	46,517	108,983	D
Stock Option (Right to Buy)^F3	$19.50	Oct 16, 2018	M	13,125	D	—	Jan 3, 2027	Common Stock	13,125	16,875	D
Stock Option (Right to Buy)^F4	$13.09	Oct 16, 2018	M	2,667	D	—	Jan 27, 2026	Common Stock	2,667	3,333	D

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
F3The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
F4The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.